IAPP, islet amyloid polypeptide, 3375

N. diseases: 183; N. variants: 3
Disease: Hyperglycemia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE We chemically synthesized glycated IAPP (AGE-IAPP) to mimic the consequence of this hormone peptide in a hyperglycemia (high blood sugar) environment. 31155148 2019
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 AlteredExpression disease BEFREE Hyperglycaemia (blood glucose >16.9 mmol/l) returned in 94% of recipients of islets expressing human proIAPP and lacking PC2, whereas recipients of islets that express human proIAPP and normal PC2 levels remained normoglycaemic for at least 16 weeks. 27999871 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Encouragingly, several proof-of-concept studies suggest that short-acting glucagon-like peptide 1 agonists or the amylin agonist pramlintide can be very effective in controlling postprandial hyperglycemia in type 2 diabetes in specific settings. 28223444 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Injectable therapies, including prandial insulin analogs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and the amylin analog pramlintide, all effectively target postprandial hyperglycemia. 28118069 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Moreover, homozygous hIAPP mice presented a severe hyperglycemia and a high lethality rate from 8 weeks onwards due to a massive destruction of β-cell mass. 28337562 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Islet amyloid polypeptide response to maximal hyperglycemia and arginine is altered in impaired glucose tolerance and type 2 diabetes mellitus. 27624579 2017
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE In vivo testing of the primers revealed an increase in demethylated amylin cfDNA in sera of non-obese diabetic (NOD) mice during T1D progression and following the development of hyperglycemia. 27111653 2016
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 AlteredExpression disease BEFREE Aggregation of human IAPP was associated with marked upregulation of proinflammatory gene expression in islets of obese hIAPP(Tg/0) mice, together with amyloid deposition and fasting hyperglycaemia. 25491100 2015
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. 19002432 2009
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE We hypothesize that glucocorticoids cause hypokalemia due to their stimulation of the Na(+)-K(+) ATPase mediated by insulin and amylin and due to their side effect of insulin resistance resulting in hyperglycemia. 19201608 2009
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE The HIP rat provides additional evidence in support of the potential role of IAPP oligomer formation toward the increased frequency of apoptosis in type 2 diabetes, a process that appears to be compounded by glucose toxicity when hyperglycemia supervenes. 15161755 2004
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE It reviews recent studies in IAPP (islet-amyloid polypeptide, or amylin) transgenic mice developing islet amyloid deposits and hyperglycemia to suggest that the process of amyloid fibril formation impairs function early and leads to beta-cell failure and eventual death. 11272181 2001
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin-resistant Mexican-American subjects with both parents affected with NIDDM (offspring) and correlated the findings with the insulin sensitivity data acquired by an insulin clamp. 9322799 1997
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 AlteredExpression disease BEFREE These data indicate that expression of human IAPP in beta cells predisposes male mice to the development of islet amyloid and hyperglycemia. 8622964 1996
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE The putative role of amylin in the hyperglycemia of aging and Type II diabetes mellitus therefore remains controversial. 1453875 1992
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 AlteredExpression disease BEFREE A significant dissociation of IAPP and insulin secretion (associated with relatively greater upregulation of IAPP secretion) is observed in response to marked hyperglycemia, suggesting that IAPP and insulin expression are differentially regulated. 1573849 1992